Role of PSMA PET/CT in imaging and management of prostate cancer.

IF 2.8 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-13 DOI:10.1097/CCO.0000000000001131

Nadine El Hoyek, Xiaolei Shi, Jason Jenkins, Wengen Chen

{"title":"Role of PSMA PET/CT in imaging and management of prostate cancer.","authors":"Nadine El Hoyek, Xiaolei Shi, Jason Jenkins, Wengen Chen","doi":"10.1097/CCO.0000000000001131","DOIUrl":null,"url":null,"abstract":"Purpose of review: In the era of precision medicine, the introduction of FDA-approved prostate-specific membrane antigen (PSMA) targeting tracers has revolutionized prostate cancer imaging. These tracers enable functional positron emission tomography (PET) imaging, allowing for precise identification of the location and extent of prostate cancer spread. This review serves as a practical guide for multidisciplinary teams caring for prostate cancer patients, outlining the current approved uses of PET imaging with PSMA tracers and exploring its future applications.Recent findings: PSMA PET/CT has become a reliable modality for initial staging in patients with intermediate-to-high risk prostate cancer, restaging in cases of biochemical recurrence and further clarifying disease status among patients with conventional imaging based nonmetastatic castrate resistant prostate cancer and metastatic prostate cancer. Additionally, it has promising roles in selecting patients for radioligand therapy, monitoring treatment response, and guiding therapeutic decision-making.Summary: PSMA PET/CT is currently a crucial imaging tool used at key stages of prostate cancer management, with ongoing research exploring its potential for additional clinical applications.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"233-239"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: In the era of precision medicine, the introduction of FDA-approved prostate-specific membrane antigen (PSMA) targeting tracers has revolutionized prostate cancer imaging. These tracers enable functional positron emission tomography (PET) imaging, allowing for precise identification of the location and extent of prostate cancer spread. This review serves as a practical guide for multidisciplinary teams caring for prostate cancer patients, outlining the current approved uses of PET imaging with PSMA tracers and exploring its future applications.

Recent findings: PSMA PET/CT has become a reliable modality for initial staging in patients with intermediate-to-high risk prostate cancer, restaging in cases of biochemical recurrence and further clarifying disease status among patients with conventional imaging based nonmetastatic castrate resistant prostate cancer and metastatic prostate cancer. Additionally, it has promising roles in selecting patients for radioligand therapy, monitoring treatment response, and guiding therapeutic decision-making.

Summary: PSMA PET/CT is currently a crucial imaging tool used at key stages of prostate cancer management, with ongoing research exploring its potential for additional clinical applications.

查看原文本刊更多论文

PSMA PET/CT在前列腺癌成像和治疗中的作用。

综述目的：在精准医疗时代，fda批准的前列腺特异性膜抗原（PSMA）靶向示踪剂的引入为前列腺癌成像带来了革命性的变化。这些示踪剂使功能性正电子发射断层扫描（PET）成像，允许精确识别前列腺癌扩散的位置和程度。本综述为多学科团队治疗前列腺癌患者提供了实用指南，概述了目前已批准的PSMA示踪剂PET成像的用途，并探讨了其未来的应用。近期发现：PSMA PET/CT已成为中高风险前列腺癌患者初始分期的可靠方式，在生化复发的情况下重新分期，并进一步明确基于常规影像学的非转移性去势抵抗性前列腺癌和转移性前列腺癌患者的疾病状态。此外，它在选择放射治疗的患者、监测治疗反应和指导治疗决策方面也有很好的作用。摘要：PSMA PET/CT是目前用于前列腺癌治疗关键阶段的重要成像工具，正在进行的研究探索其在其他临床应用中的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.